Preclinical evaluation of the PI3K/Akt/mTOR pathway in animal models of multiple sclerosis-Reference-Cited by-同舟云学术

Preclinical evaluation of the PI3K/Akt/mTOR pathway in animal models of multiple sclerosis

Published:2018-01-03 Issue:9 Volume:9 Page:8263-8277
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Mammana Santa¹,Bramanti Placido²,Mazzon Emanuela²,Cavalli Eugenio¹,Basile Maria Sofia¹,Fagone Paolo¹,Petralia Maria Cristina³,McCubrey James Andrew⁴,Nicoletti Ferdinando¹,Mangano Katia¹

Affiliation:

1. Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy

2. IRCCS Centro Neurolesi Bonino-Pulejo, Messina, Italy

3. Department of Educational Sciences, University of Catania, Catania, Italy

4. Department of Microbiology and Immunology, Brody School of Medicine, East Carolina University, Greenville, NC, USA

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 80 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vortioxetine ameliorates experimental autoimmune encephalomyelitis model of multiple sclerosis in mice via activation of PI3K/Akt/CREB/BDNF cascade and modulation of serotonergic pathway signaling;European Journal of Pharmacology;2024-11

2. The iron maiden: Oligodendroglial metabolic dysfunction in multiple sclerosis and mitochondrial signaling;Neuroscience & Biobehavioral Reviews;2024-09

3. The PI3K/Akt signaling axis and type 2 diabetes mellitus (T2DM): From mechanistic insights into possible therapeutic targets;Cell Biology International;2024-05-29

5. The beneficial role of autophagy in multiple sclerosis: Yes or No?;Autophagy;2023-09-25